Nicotinamide and Tumor Radiosensitization
Author Information
Author(s): A. Rojas, R.J. Hodgkiss, M.R.L. Stratford, M.F. Dennis, H. Johns
Primary Institution: CRC Gray Laboratory, Mount Vernon Hospital, Northwood, UK
Hypothesis
Can varying doses of nicotinamide enhance tumor radiosensitization when combined with carbogen?
Conclusion
Nicotinamide doses of 0.05 to 0.5 mg/g significantly increase the radiosensitivity of rodent tumors compared to treatments under air-breathing conditions.
Supporting Evidence
- Plasma concentrations of nicotinamide were dose-dependent, with peak levels observed within 15 minutes.
- Significant increase in tumor radiosensitization was observed with carbogen combined with nicotinamide.
- Enhancement ratios increased with higher doses of nicotinamide.
Takeaway
This study shows that giving mice a vitamin called nicotinamide before radiation treatment helps make the radiation work better against tumors.
Methodology
Adult CBA male mice were used to measure plasma concentrations of nicotinamide and assess tumor radiosensitization with various doses combined with carbogen.
Limitations
The study's findings may not directly translate to humans due to differences in drug metabolism and tumor biology.
Participant Demographics
Adult CBA male mice, 10 to 15 weeks old.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.00001
Want to read the original?
Access the complete publication on the publisher's website